An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines

Part of paid clinical trials in Carlsbad, California.

Sponsor
Qualia Life Sciences
Study ID
NCT06953518
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Inflammation

Eligibility Criteria

Sex
ALL
Age
45 Years - 79 Years
Healthy Volunteers
Accepted

Interventions

  • Qualia Senolytic — DIETARY_SUPPLEMENT
    Qualia Senolytic manufactured by Qualia Life Science

Study Details

This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.

Key Dates

Start date
May 12, 2025
Status verified
Apr 2025
Primary completion
May 18, 2025
Completion
May 18, 2025

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Qualia Senolytic

Primary Outcome Measure

Olink Target 48 Cytokine panel - TNF, IL1B, CXCL8, VEGFA [ Time Frame: 1 week ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Qualia Life SciencesCarlsbadCalifornia92011
Abhi Argagh
[email protected]
855-281-2328

Find similar trials in Carlsbad, CA

By research site
Qualia Life Sciences· Carlsbad, CA

Related Studies